Recent Updates
Recently added Catalysts

Smallpox Vaccine

Phase 1

HIV Infections | Monoclonal antibody | Infectious Disease |Bristol-Myers Squibb Company|Last Updated: Sep 26, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002261A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated VolunteersPHASE1 COMPLETED - - -Sep 26, 20071 United States
Unlock Drug Trial Details
Study Design & Arms
PurposePREVENTION
Interventions
NameTypeDescription
Smallpox VaccineBIOLOGICAL -
HIVAC-1eBIOLOGICAL -
gp160 Vaccine (MicroGeneSys)BIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria Concurrent Medication: Allowed: * All drugs, medications, and therapy which, by virtue of direct pharmacologic action or possible drug interaction, could influence the intended effects of the study vaccine or mask its side effects may be concomitantly administered only by presc...

Countries:United States
Unlock Eligibility Criteria